[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572167":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":60,"collaborators":25,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":25,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":25,"overallStatus":83,"whyStopped":25,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (control group)","ACTIVE_COMPARATOR","lt will include 28 participants suffering from PD who will take vitamin D (vit D) supplementations for three consecutive menstrual cycles.",[13],"Other: Vitamin D",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B (study group)","EXPERIMENTAL","lt will include 28 participants suffering from PD who will take vitamin D (vit D) supplementations as in group A in addition to Bioptron for 20 min daily for 7 days before menstrual cycle along with the first three days of menstrual flow for three consecutive menstrual cycles.",[19,13],"Other: Bioptron Pro 1 Class II",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Bioptron Pro 1 Class II","Bioptron Pro 1 Class II: Made by Bioptron AG, Wollerau, Switzerland, a device with a floor stand emits a polarized light lamp. The device has an ergonomic table stand that can be combined with a functional floor stand, allowing flexible use in domestic and professional environments. easily adjustable height and head inclination and the ability to rotate the device head up to 360 allow a convenient usage of nearly any position. Treatments can easily be timed by a control panel down to 30 seconds, an integrated distance rod ensures the recommended distance from the skin surface It will be used for the treatment procedures for all participants in group B only with the following parameters, Wavelengths ranging from 480-3400 nm, Degree of polarization \\>95% (590 - 1550 nm), Specific power density Av. 40 mW\u002Fcm2 Light energy per minute av.2.4 J\u002Fcm2, Light Intensity per min. 10.000 lux, Weight without stand 3.4 kg and Weight with stand7.8 kg ,Energy consumption in sleep mode0.5",[15],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Vitamin D","All participants in both groups will take this supplements daily for 3 months",[9,15],[31],{"name":32,"affiliation":5,"role":33},"Doaa A Osman","STUDY_CHAIR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Eman SA Eldeeb","CONTACT","01012674761","emansalehpt@gmail.com",{"name":41,"role":37,"phone":42,"phoneExt":25,"email":43},"Manal A El-Shafei, Lecturer","01220664518","manal.ahmed@pt.cu.edu.eg",[45],{"facility":46,"status":25,"city":47,"state":48,"zip":49,"country":48,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Faculty of Physical Therapy","Giza","Egypt","12511","EG",{"type":52,"coordinates":53},"Point",[54,55],31.20861,30.00944,{"lat":55,"lon":54},[58],{"name":36,"role":37,"phone":59,"phoneExt":25,"email":25},"0201012674761",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Eman Saleh Ahmed Eldeep","Master student at Faculty of Physical Therapy, Cairo University","100572167","effect-of-bioptron-on-primary-dysmenorrhea-100572167",false,"NCT06729749","Effect of Bioptron on Primary Dysmenorrhea","Effect of Bioptron on Primary Dysmenorrhea: a Randomized Controlled Trial","Inclusion Criteria:\n\nAll females will be clinically diagnosed by the gynecologist with primary dysmenorrhea.\n\n* Self-reported history of PD, at least moderate pain due to menstrual cramps (\\>4 on VAS)\n* They have moderate symptoms of PD on the WaILDD questionnaire, (5-12) Teheran et al., 2018).\n* Their ages will be ranged from 18-24 years old.\n* Their BMI will be less than 30 kg\u002Fm².\n* Being a virgin.\n* Having regular menstruation for the last 6 months (every 28-30 days with no intermittent bleeding).\n* Voluntary acceptance to participate in the study.\n\nB) Exclusion Criteria:\n\nParticipants will be excluded if they have:\n\n* Musculoskeletal or neurological disorders.\n* Patients with a history of phototherapy allergy.\n* Professional athletes (Jill et al., 2012).\n* Secondary dysmenorrhea pathology such as (endometriosis, fibroids, adenomyosis, and pelvic inflammatory disease)\n* Menstrual irregularity.\n* Using hormonal contraception (such as contraceptives or injections).","FEMALE","18 Years","24 Years",{"count":75,"type":76},56,"ESTIMATED","INTERVENTIONAL",[79],"NA","This study will be conducted to determine the effect of bioptron on PD through the assessment of serum progesterone level, and pain level measured by pressure algometry in addition to evaluation of the symptoms of PD and its effect on girl's quality of life through valid and reliable questionnaires which will be of valuable benefits in the women's health fields.",[82],"Dysmenorrhea","NOT_YET_RECRUITING","2024-12-07",{"date":86,"type":87},"2024-12-11","ACTUAL",{"date":89,"type":76},"2024-12-15",{"date":91,"type":76},"2025-06-30",{"name":5,"class":6},1]